A Bioequivalence Study of PP3M in Patients With Schizophrenia
A Randomized, Open-label, Multicenter, Two-formulation, Multiple-dose, Parallel-design Bioequivalence Study of Paliperidone Palmitate Injection (3M) in Chinese Patients With Schizophrenia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Clinical Trials Information Group Officer
- Phone Number: 86-0311-69085587
- Email: ctr-contact@cspc.cn
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100120
- Recruiting
- Beijing Anding Hospital Capital Medical University
-
Contact:
- Gang Wang, M.D.
- Phone Number: 010-58303236
- Email: adyyjg@163.com
-
Principal Investigator:
- Gang Wang, M.D.
-
Principal Investigator:
- Anning Li, M.D.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 to 65 years old (including 18 and 65 years old).
- Patients diagnosed with schizophrenia (by ICD-10 criteria) before screening.
- Weight: male patients with weight ≥50.0 kg, female patients with weight ≥45.0 kg, with the body mass index of 19.0~35.0 kg/m^2 (including 19.0 and 35.0).
- Positive and Negative Syndrome Scale (PANSS) total score lower than 70 at screening and baseline.
- Clinical Global Impression-Severity (CGI-S) lower than 4 at screening and baseline.
- Patients and their guardians voluntarily sign the ICF and are able to comply with the requirements of the study.
Exclusion Criteria:
- Be allergic, or have a clear history of allergies to trial drugs and components.
- Patients with cardiovascular, liver, kidney, gastrointestinal, psychiatric, or neurological diseases that may affect participation in the trial, as determined by the investigator.
- History of tardive dyskinesia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Test product
Paliperidone Palmitate Injection (3M), 1.75 mL: 350 mg
|
Intramuscular injection
Other Names:
|
|
Active Comparator: Reference product
Invega Trinza, 1.75 mL: 350 mg
|
Intramuscular injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cmax,ss,
Time Frame: Up to Day456
|
Maximum plasma concentration at steady state
|
Up to Day456
|
|
AUCτ,ss
Time Frame: Up to Day456
|
Area under the plasma concentration-time curve over a dosing interval at steady state
|
Up to Day456
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Title:Incidence and severity of adverse events (AEs)
Time Frame: Up to Day456
|
The frequency and degree of harmfulness of adverse events
|
Up to Day456
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Gang Wang, M.D., Beijing Anding Hospital Capital Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SYHF2037-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.